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Abstract: Antimicrobial susceptibility testing (AST) is routinely used to establish predictive antibiotic
resistance metrics to guide the treatment of bacterial pathogens. Recently, a novel phenotype termed
“bicarbonate (NaHCO3)-responsiveness” was identified in a relatively high frequency of clinical
MRSA strains, wherein isolates demonstrate in vitro “susceptibility” to standard β-lactams (oxacillin
[OXA]; cefazolin [CFZ]) in the presence of NaHCO3, and in vivo susceptibility to these β-lactams
in experimental endocarditis models. We investigated whether a targeted phenotypic-genotypic
screening of MRSA could rule in or rule out NaHCO3 susceptibility upfront. We studied 30 well-
characterized clinical MRSA bloodstream isolates, including 15 MIC-susceptible to CFZ and OXA in
NaHCO3-supplemented Mueller–Hinton Broth (MHB); and 15 MIC-resistant to both β-lactams in
this media. Using a two-tiered strategy, isolates were first screened by standard disk diffusion for
susceptibility to a combination of amoxicillin-clavulanate [AMC]. Isolates then underwent genomic
sequence typing: MLST (clonal complex [CC]); agr; SCCmec; and mecA promoter and coding region.
The combination of AMC disk susceptibility testing plus mecA and spa genotyping was able to predict
MRSA strains that were more or less likely to be NaHCO3-responsive in vitro, with a high degree
of sensitivity and specificity. Validation of this screening algorithm was performed in six strains
from the overall cohort using an ex vivo model of endocarditis. This ex vivo model recapitulated the
in vitro predictions of NaHCO3-responsiveness vs. nonresponsiveness above in five of the six strains.
Keywords: methicillin-resistant Staphylococcus aureus (MRSA); β-lactam susceptibility; sodium bicar-
bonate (NaHCO3); antimicrobial susceptibility testing (AST); genome sequencing
1. Introduction
Antibiotic resistance is a major threat to healthcare initiatives worldwide [1–3]. De-
spite the availability of extensive in vitro testing methods and international consensus
committee interpretive guidelines to aid in treatment practices, antibiotic resistance has not
abated [3–6]. Of note, there has been a lack of innovation in the development of in vitro
methods that mimic the host microenvironment and milieu during active infection [7–9].
Guideline committees, such as the Clinical and Laboratory Standards Institute (CLSI)
and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) generally
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rely heavily on “standard” in vitro methods of antimicrobial susceptibility testing (AST)
to determine minimum inhibitory concentrations (MICs) of antibiotics towards various
pathogens. These standardized methods utilize specific growth media, such as Mueller–
Hinton Broth/Agar (MHB/A), for most bacterial pathogens [4,10]. For select antibiotics,
specific supplements are included or depleted to ensure appropriate expression of resis-
tance genes or prevent degradation of antibiotics in an artificial medium [11–13]. However,
this medium, even with alterations, is not necessarily reflective of host environmental
conditions pathogens may face during infection [7]. Primary AST methods employed in
clinical microbiology laboratories include broth microdilution (BMD), agar dilution, and/or
disk or gradient diffusion strip assays [6,14,15]. Manual BMD and agar dilution MICs
are time- and labor-intensive and not widely used [6,16]. Advancements have been made
to machine-automate this process (e.g., the Becton–Dickinson Phoenix or the BioMérieux
Vitek 2 systems [17,18]). Increased ease and cost-effectiveness of bacterial whole genome
sequencing (WGS) may allow clinical microbiology laboratories to incorporate genomic
identification of specific resistance genes and mutations as an accompaniment to routine
in vitro screening methods in the near future [17,19–22]. To date, only a relatively small
number of laboratories have adopted routine WGS, mostly for molecular epidemiology
and infection control purposes.
Recent studies have highlighted potential limitations of relying on standard methods
of AST to determine relevant antibiotic resistance in specific infection settings [8,9,23–26].
These studies utilized media that may be more reflective of the host environment, such
as tissue culture media (e.g., RPMI) or MHB supplemented with NaHCO3, the body’s
primary biological buffer, to perform in vitro AST. Results of such studies suggest that it
could be possible that “antibiotic resistance levels by MICs” determined in host-like media
are better predictors of host infection outcomes in both murine and rabbit systemic infec-
tion models [8,9,23–25]. Our laboratory has recently published a series of investigations
documenting the following in terms of MIC testing of MRSA in NaHCO3-supplemented
MHB: (i) ~33% and ~75% frequency of in vitro susceptibility of MRSA to OXA and CFZ,
respectively; (ii) better clearance of in vitro NaHCO3-responsive MRSA from experimental
cardiac vegetations in both ex vivo and in vivo models; and (iii) definition of important
mechanisms involved in this NaHCO3-responsive phenotype (e.g., penicillin-binding
protein 2a (PBP2a) production, translocation and maturation) [23,26–28].
The aim of this exploratory and hypothesis-generating study was to combine current
AST methods with targeted genetic sequencing to identify MRSA that may potentially
respond to standard β-lactam therapy in vivo [23,26].
2. Results
2.1. Identification of Phenotypic and Genotypic Traits Associated with NaHCO3-Responsiveness
Within this 30-isolate collection (summarized in Table S1), two mecA genotypes were
detected, termed “susceptible 2” and “resistant 2”, as per Harrison et al. [29]. The suscepti-
ble 2 genotype has a T at the mecA promoter -7 ribosomal-binding site (RBS), whereas the
resistant 2 genotype has a G at this site. This promoter single nucleotide polymorphism
(SNP) is associated with decreased mecA transcription in susceptible 2 MRSA as compared
to resistant 2 isolates [29]. Both Chi-squared and Fisher’s exact analysis revealed that the
susceptible 2 genotype were significantly associated with a NaHCO3-responsive phenotype
(Table S2, p < 0.01). However, the linkage between the responsiveness phenotype and the
susceptible 2 genotype was highly sensitive (93.3%, 95% CI [68.1–99.8]), the use of this
single metric as a predictor of responsiveness resulted in a specificity of only 66.7% (95%
CI [38.4–88.2]).
We investigated the correlation between NaHCO3-responsiveness and susceptibility
to amoxicillin + clavulanate (AMC) by standard disk diffusion assay. AMC disks were
employed due to their commercial availability (in comparison to penicillin–clavulanate
combination disks). The 2012 CLSI-defined staphylococcal breakpoints for AMC by disk
diffusion are given as S ≥ 20 mm and R ≤ 19 mm [30]. Of note, these CLSI parameters
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were ultimately replaced by generally reporting ‘OXA susceptibility’ as a surrogate for
presumed susceptibility to such β-lactam-β-lactamase inhibitor combinations and have not
been updated since 2013 [31–33]. Interestingly, despite the published association between
the mecA susceptible 2 genotypes and susceptibility to penicillin + CA by E-test [29], we
found no significant correlations between this genotype and susceptibility to AMC by disk
diffusion, using the above breakpoints (Table 1).
Table 1. Disk diffusion susceptibility to β-lactam/β-lactamase inhibitors and genotypes for various loci in NaHCO3-
responsive and nonresponsive MRSA strains.





Type agr Type CC Type SCCmec Type β-lactamase (±)
MRSA 11/11 16 (S) susceptible 2 t008 agr I 8 IV +
MW2 20 (S) susceptible 2 t128 agr III 1 IV +
BCVA289 16 (S) susceptible 2 t008 agr I 8 IV +
PB 031-038 11 (R) resistant 2 Unknown B agr I 8 IV +
PB 004-193 15 (S) susceptible 2 t008 agr I 8 IV +
PB 043-043 15 (S) susceptible 2 t008 agr I 8 IV +
PB 077-107 13 (R) susceptible 2 t002 agr II 5 II +
C48 18 (S) susceptible 2 t008 agr I 8 IV +
C42 15 (S) susceptible 2 t008 agr I 8 IV +
C13 15 (S) susceptible 2 t008 agr I 8 IV +
C32 18 (S) susceptible 2 t002 agr II 5 IV +
C30 19 (S) susceptible 2 t008 agr I 8 IV +
C24 16 (S) susceptible 2 t008 agr I 8 IV +
C38 14 (R) susceptible 2 t008 agr I 8 IV +
RB 300-087 18 (S) susceptible 2 t2265 agr I 45 IV +
Nonresponsive Strains (n = 15)
Strain AMC mecAGenotype
Ridom spa
type agr type CC type SCCmec type β-lactamase (±)
BMC1001 15 (S) resistant 2 t064 agr I 8 IV +
C5 26 (S) resistant 2 t242 agr II 5 II +
RB 067-227 18 (S) susceptible 2 t128 agr III 1 IV +
RB 010-016 11 (R) resistant 2 t002 agr II 5 II +
PB 027-133 13 (R) resistant 2 t002 agr II 5 II +
PB 088-180 23 (S) resistant 2 t002 agr II 5 II +
RB 034-221 23 (S) resistant 2 t002 agr II 5 II +
C7 14 (R) susceptible 2 t008 agr I 8 IV +
C36 14 (R) resistant 2 t002 agr II 5 II +
C15 16 (S) resistant 2 t064 agr I 8 IV +
PB 300-111 17 (S) susceptible 2 t051 agr I 8 IV +
PB 321-236 23 (S) resistant 2 t003 agr II 5 II +
C3 14 (R) susceptible 2 t008 agr I 8 IV +
PB 017-037 24 (S) resistant 2 t002 agr II 5 II +
RB 057-171 15 (S) susceptible 2 t9878 agr III 1 IV +
A Zone diameter (mm) for amoxicillin + clavulanate (AMC) disk diffusion assay, classified as Resistant = (R) or Susceptible = (S) based on a
newly defined breakpoint of R ≤ 14 mm and S ≥ 15 mm; B Unknown repeat succession: r11r19r12r05r25.
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For the present study, to try to improve the utility of AMC disk diffusion results
in screening for NaHCO3-responsive MRSA, we defined a distinct set of breakpoints
(S ≥ 15 mm and R ≤ 14 mm) based on the overall zone size median among the overall
isolate-set, as well as the zone size mode among the NaHCO3-responsive cohort. Applying
this revised metric to our 30 MRSA strains, “susceptibility” as defined by AMC disk
diffusion profiles correctly identified 12/15 NaHCO3-responsive isolates (sensitivity of
80.0% (95% CI [51.9–95.7]). However, the specificity of this metric was only 33.3% (95% CI
[11.8–61.6%]) (Table S2). Furthermore, the receiver operator curve (ROC) analysis revealed
the AUC of AMC susceptibility testing as a predictor of NaHCO3-responsiveness to be less
than 0.5 (data not shown), indicative of a poor diagnostic test.
To improve the specificity of the AMC disk diffusion assay for predicting the NaHCO3-
responsive phenotype, we combined this latter assay with targeted genotypic profiling (i.e.,
MLST [CC], spa, agr, SCCmec and mecA coding-promoter genotypes) (Table 1 and Table S2).
These analyses revealed that NaHCO3-responsive isolates could be predicted by their sus-
ceptibility to AMC in combination with the presence of the mecA “susceptible 2” genotype,
plus either spa type t008 or t002 (Table 2 and Table S2). Although this combinatorial method
had a sensitivity of only 66.7% (95% CI 38.4–88.2%), it exhibited 100% specificity with a 95%
CI of 78.2–100%. Thus, the initial screening of strains by AMC disk diffusion, if ‘resistant’
by the above-customized breakpoints, would potentially eliminate a need for subsequent
genotypic analysis of MRSA strains.
Table 2. Selected screening criteria for identifying NaHCO3-responsive and nonresponsive MRSA.
Criteria are AMC susceptible, mecA “susceptible 2” genotype, spa type t008 or t002. Only strains
meeting all three of these criteria are considered NaHCO3-responsive (Chi-squared and Fisher’s
exact p < 0.01).
Algorithm Criteria Met? NaHCO3-Responsive Nonresponsive
Criteria met 10 0
Criteria not met 5 15
Statistic Value 95% CI
Sensitivity 66.67% 38.38% to 88.18%
Specificity 100.00% 78.20% to 100.00%
2.2. Ex Vivo Validation of NaHCO3-Responsiveness Screening Criteria
The NaHCO3-responsive strains chosen for ex vivo validations (as defined by BMD
testing NaHCO3-supplemented MHB; C24, C32, C38) met all three of the above in vitro
screening metrics (Table 1). In contrast, although all the nonresponsive strains (as defined
by BMD testing; RB 057-171, C15, PB 321-236) displayed susceptibility to AMC by disk
diffusion, only one strain had a susceptible mecA genotype, and none displayed a t008 or
t002 spa type (Table 1).
In the ex vivo model, five of the six validation strains recapitulated the responsiveness
phenotypes, as well as the algorithm predictions proposed in vitro. Thus, responsive
strains C48 and C32 demonstrated significant reductions in MRSA counts by OXA over the
72 h exposures in the SEV model, especially early (24 h); however, growth of the C24 strain
was not inhibited by OXA in this model (Figure 1A). None of the nonresponsive strains
were inhibited by OXA by the 72 h time point (Figure 1B), although strain RB 057-171
demonstrated early OXA-killing (24 h).




Figure 1. Simulated endocarditis vegetation (SEV) tissue burdens following OXA treatment of (A) NaHCO3-responsive or 
(B) Nonresponsive MRSA. SEVs containing MRSA were exposed to RPMI tissue culture medium with or without OXA 
exposure at doses that simulate human serum PK/PD. Vegetations were quantitatively cultured for MRSA CFU/g at 0, 4, 
8, 24, 48, and 72 h time points. Statistics were performed on the CFU/g present in untreated samples versus OXA treatment 
at the indicated time point by a Student’s t-test (* p < 0.05). 
3. Discussion 
Given the complexity, costs and treatment-related toxicities of current standard-of-
care therapies for invasive MRSA infections (e.g., vancomycin, daptomycin, linezolid) 
[34–36], the use of effective, inexpensive and well-tolerated antibiotics (such as β-lactams) 
would be advantageous. However, current clinical guidelines discourage the use of β-
lactams in MRSA infections because of their uniform “in vitro resistance” to such agents 
by standard MIC testing [15,32]. As noted above, we have previously identified that a 
significant proportion of clinical MRSA isolates exhibit susceptibility in vitro to standard 
β-lactams if tested in the presence of NaHCO3 [26]. However, routine AST of all MRSA 
isolates in both standard and NaHCO3-supplemented media by BMD would involve ad-
ditional reagent and materials costs, technical effort, as well as turnaround time implica-
tions for clinical microbiology laboratories. 
In the present study, we attempted to establish a specific algorithm for the identifi-
cation of NaHCO3-responsive MRSA utilizing both standard methods currently em-
ployed by clinical microbiology laboratories, as well as genotypic screening modes. This 
is a preliminary and exploratory study designed to generate metrics for specifically iden-
tifying NaHCO3-responsive strains in vitro that will likely respond to β-lactam therapy in 
vivo. Our proposed algorithm (summarized in Figure 2) relies on initial screening of 
MRSA by a standard disk diffusion assay using AMC, employing a susceptibility break-
point of ≥15 mm zone sizes. Following this initial phenotypic ‘checkpoint’, isolates that 
meet this criterion (i.e., AMC-‘susceptible’) would then undergo targeted genomic se-
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exposure at doses that simulate human serum PK/PD. Vegetations were quantitatively cultured for MRSA CFU/g at 0, 4, 8,
24, 48, and 72 h time points. Statistics were performed on the CFU/g present in untreated samples versus OXA treatment at
the indicated time point by a Student’s t-test (* p < 0.05).
3. Discussion
Given the complexity, costs and treatment-related toxicities of current standard-of-care
therapies for invasive MRSA infections (e.g., vancomycin, daptomycin, linezolid) [34–36],
the use of effective, inexpensive and well-tolerated antibiotics (such as β-lactams) would
be advantageous. However, current clinical guidelines discourage the use of β-lactams in
MRSA infections because of their uniform “in vitro resistance” to such agents by standard
MIC testing [15,32]. As noted above, we have previously identified that a significant
proportion of clinical MRSA isolates exhibit susceptibility in vitro to standard β-lactams if
tested in the presence of NaHCO3 [26]. However, routine AST of all MRSA isolates in both
standard and NaHCO3-supplemented media by BMD would involve additional reagent
and materials costs, technical effort, as well as turnaround time implications for clinical
microbiology laboratories.
In the present study, we attempted to establish a specific algorithm for the identifica-
tion of NaHCO3-responsive MRSA utilizing both standard methods currently employed
by clinical microbiology laboratories, as well as genotypic screening modes. This is a
preliminary and exploratory study designed to generate metrics for specifically identifying
NaHCO3-responsive strains in vitro that will likely respond to β-lactam therapy in vivo.
Our proposed algorithm (summarized in Figure 2) relies on initial screening of MRSA
by a standard disk diffusion assay using AMC, employing a susceptibility breakpoint
of ≥15 mm zone sizes. Following this initial phenotypic ‘checkpoint’, isolates that meet
this criterion (i.e., AMC-‘susceptible’) would then undergo targeted genomic sequenc-
ing to specifically determine their mecA coding and RBS sequences, and spa genotypes
to identify strains as potential candidates for β-lactam therapy. As WGS becomes more
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frequently used in clinical laboratories, these provisional genotypic criteria may be fur-
ther refined as screening metrics to predict NaHCO3-responsiveness with a higher degree
of sensitivity and specificity. This targeted genotyping profiling presented here differs
from currently employed strategies for WGS-based AST, wherein isolates are screened for
specific genes/alleles with known mechanistic associations with well-defined antibiotic
resistance mechanisms [17,20]. In contrast, our current data suggest that the specific mech-
anisms involved in the β-lactam-NaHCO3-responsiveness phenotype are multifactorial,
and not related to perturbations of a single gene locus [23,28]. Thus, the screening method
described here relies on the association of certain genotypic-phylogenetic markers with the
β-lactam-NaHCO3-responsiveness phenotype, although these genotypes may not directly
underlie this phenotype.
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cefoxitin but ‘susceptible’ to AMC, based on a modified breakpoint zone size cut off of ≥15 , then undergo targeted
genotyping. Only those such isolates which possess both the mecA “susceptible 2” plus either spa type t008 or t002 genotypes
would then be considered as potentially “in vivo susceptible” to β-lactams.
The screening algorithm above is highly specific; thus, strains that do not fulfill
all three phenotypic-genotypic metrics are unlikely to be β-lactam-NaHCO3-responsive.
However, this algorithm lacks the sensitivity inherent in direct AST of MRSA isolates in
NaHCO3-containing media by BMD MIC. Despite this lack of sensitivity, this proposed
screening algorithm underscores the ability to classify MRSA as unlikely candidates for
β-lactam therapy, and is a highlight of this approach.
Manual BMD AST is both time- and labor-intensive, and therefore, many clinical
laboratories either automate the process using commercial systems or disk diffusion testing
when CLSI interpretive criteria are available [37,38]. Theoretically, alternative media (e.g.,
NaHCO3-supplemented) could be incorporated into commercially-available automated
systems, although such changes would require extensive diagnostic validations and quality
controls by manufacturers. However, if clinical trial data demonstrate improvements in
patient outcomes associated with the use of a β-lactam over alternative therapies, this
change in diagnostics might well be driven by clinical need.
Our previous larger screening of a 58 isolate MRSA collection, from which the 30 isolate
subset used in this study was derived, revealed a statistical linkage between the presence
of CC8 and spa t008 genotypes and the NaHCO3-responsive phenotype [26]. This indicated
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that many isolates exhibiting the NaHCO3-responsive phenotype might have arisen from a
specific clonal lineage. However, this link was not strong enough to utilize these genotypes
as the sole method to identify NaHCO3-responsive MRSA. Formal phylogenetic and
bioinformatic analyses of a larger number of NaHCO3-responsive/nonresponsive MRSA
will be required to provide further, more definitive, insights into the ancestral origins of
this phenotype and point to additional genetic sequence targets to aid in the rapid genomic
identification of such strains.
The mecA gene locus encodes the alternative penicillin-binding protein PBP2a, which
is considered to be the primary determinant of β-lactam resistance in MRSA [39,40]. Many
clinical laboratories routinely screen for the presence of mecA. However, intra-locus SNP
analysis (as done in this study) is not generally employed to subcategorize mecA geno-
types; such analytics appear to be informative, given the importance of specific mecA
coding sequence-promotor genotypes in determining susceptibility to certain β-lactam-β-
lactamase inhibitor combinations [29]. Of interest, we determined that certain “susceptible”
mecA genotypes were significantly associated with the NaHCO3-responsive phenotype.
However, screening for specific mecA genotypes alone did not appear to be highly spe-
cific (66.7%, CI [38.4–88.2%]), and could result in many MRSA isolates being erroneously
identified as NaHCO3-responsive as a single determinant.
Most of our six validation strains exhibited the expected outcomes as predicted
by the algorithm in the ex vivo SEV model. Interestingly, the nonresponsive strain RB
057-171 (as determined by in vitro testing in NaHCO3-containing media), displayed an
initial reduction in bacterial vegetation burden following OXA treatment at 24 h. This
strain displayed susceptibility to AMC by disk diffusion and also possessed the mecA
“susceptible 2” genotype but did not possess a spa type of t008 or t002. This outcome
indicates that strains possessing the mecA “susceptible 2” genotype may demonstrate some
short-term β-lactam susceptibility in the SEV model, which abates over a longer exposure
time-course. This finding further emphasizes the need for additional screening metrics (i.e.,
spa typing) to ‘rule out’ strains as candidates for clinical β-lactam treatment. The in vitro
responsive strain, C24, was not inhibited by OXA in the SEV model, despite meeting all
three algorithmic screening criteria. This underscores the need for further validation testing
of a larger collection of strains in both ex vivo and in vivo models.
The discovery of bacterial antimicrobial susceptibility profiles as they occur during
host infection and determining genetic signatures associated with these phenotypes can
usher in a new era of precision antibiotic treatment practices. As WGS and other genotyping
methods become faster, cheaper, and more widespread, the identification of specific se-
quences and genomic markers associated with antibiotic-resistant and antibiotic-susceptible
phenotypes will undoubtedly be employed by many clinical microbiology laboratories.
Today, WGS is considered the state-of-the-art method for clonality testing of S. aureus,
having replaced outdated methods such as pulsed-field gel electrophoresis [41–44].
Turnaround times of data to clinicians caring for the patients in real-time, as well as
microbiology laboratory costs (both technical and reagents), are important considerations
for the implementation of novel AST screening methods. Our current best estimates are
that the combination of AMC disk diffusion plus spa typing/mecA sequencing is estimated
to take ~3 days. In contrast, BMD testing of strains in parallel in both standard media, as
well as onsite preparation of NaHCO3-supplemented media, is estimated to take up to
4 days. Further, CA-MHB-NaHCO3 BMD testing would certainly be more laborious for the
laboratory than AMC disk diffusion testing. Finally, bacterial whole genome sequencing
(WGS) and annotation (if all equipment is onsite) are predicted to take ~2–3 days. These
estimates are dependent on the availability of adequately trained laboratory staff seven
days a week, daily batching of testing, and pre-preparation of media/reagents [45].
It is difficult to put a comparative and accurate cost-out for each of the above three po-
tential screening methodologies. However, it is generally agreed that sequencing, whether
using next-generation sequencing, targeted sequencing of one or more genes of interest
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(e.g., using Sanger sequencing) is more expensive than disk diffusion or MIC testing; this
includes both cost of sequencing preparation, sequencing itself, as well as for analytics.
Our study has certain distinct limitations, including: (i) a relatively small sample size
of β-lactam-NaHCO3-responsive and -nonresponsive MRSA; this predictive algorithm
needs to be applied to a significantly larger cohort of isolates to further examine its sensitiv-
ity and specificity; current work is being undertaken to screen a much larger collection of
skin and soft tissue MRSA isolates (n = 105) to identify further NaHCO3-responsive isolates
to aid in the validation of this algorithm; (ii) lack of geographic diversity of the study
strains (US only); multi-national strain cohorts need to be evaluated with this algorithm;
(iii) focus only upon bloodstream isolates; additional study of isolates from other common
infection syndromes (e.g. skin and soft tissue infections) needs to be carried out; and (iv)
limited scope of validation of this in vitro predictive algorithm in translational ex vivo and
in vivo models of invasive MRSA infections treated with selected β-lactams; current work
is being undertaken to validate NaHCO3-responsive and nonresponsive strains in a rabbit
model of infective endocarditis (IE).
4. Materials and Methods
4.1. Bacterial Strains, Growth Conditions, and Susceptibility Testing
A collection of 15 NaHCO3-responsive and 15 NaHCO3-nonresponsive isolates was
used in this study. All of these isolates have been previously characterized for their
susceptibility to OXA and CFZ in the presence or absence of NaHCO3 [23,26,28,29]. This
30-isolate cohort represents clonal complex types common in worldwide circulation, as
well as a diversity of baseline OXA and CFZ MICs (as determined in CA-MHB) (Table S1).
All isolates were stored at −80 ◦C until thawed for use and cultured on Tryptic Soy Agar
(TSA). For MIC testing, we utilized BMD; strains were cultured in cation-adjusted Mueller
Hinton Broth (CA-MHB) ± 100 mM Tris buffer (to maintain a stable pH) ± 44 mM NaHCO3
(pH 7.3 ± 0.1). For MIC testing in OXA, 2% NaCl was also included in the MHB. Although
44 mM of NaHCO3 is above standard human blood levels, it reflects tissue levels [46]. In
addition, MIC determinations among MRSA using this latter NaHCO3 level (vs. 25 mM)
correlates better with ex vivo and in vivo infection model outcomes [23,27]. For MIC testing,
isolates were grown overnight, then diluted into the specific AST testing media-of-interest,
as previously described [23]).
Harrison et al. [29] have previously shown among selected MRSA isolates, there
is a significant relationship between i) specific mecA coding region and RBS promoter
genotypes; and ii) in vitro E-test susceptibility to combinations of β-lactams (e.g., penicillin)
with clavulanic acid (CA). In the current study, we employed commercially available AMC
disks in a Kirby–Bauer diffusion assay on MHA using a standard inoculum [47]. Based on
the overall distribution of zone diameters among the current 30 isolate collection, as well
as mean and modal zone sizes, we used customized breakpoints of “susceptible” ≥ 15 mm
and “resistant” ≤ 14 mm. Assays were done at least in duplicate on separate days, with
zone size readings done blinded as to the β-lactam-NaHCO3-responsiveness phenotype.
4.2. mecA, Clonal Complex (CC), agr, SCCmec, and spa Genotyping
To identify specific polymorphisms within the mecA promoter and coding regions,
DNA was isolated from MRSA strains by chelation (InstaGene-Matrix, Bio-Rad, Hercules,
CA, USA) and the mecA region amplified by PCR using Phusion High-Fidelity DNA
Polymerase (New England Biolaboratories) (amplification and sequencing primers listed
in Table S3). PCR products were purified using the PureLink PCR Micro Kit (Invitrogen,
Waltham, MA, USA) and sequenced by GeneWiz LLC.
For determination of CC, SCCmec, agr, and spa genotypes, S. aureus DNA was isolated
by boiling, followed by treatment with 20 µg/mL lysostaphin (Sigma-Aldrich, Merck
KGaA, Darmstadt, Germany); the lysate was then used as a template for PCR. spa typing
was performed as described [48], and the resulting repeat patterns were used to infer
MLST–based CC types [49]. SCCmec typing was performed using a molecular beacon-
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based real-time PCR assay [50]. Finally, agr typing was performed using a modified
version multiplex PCR assay [51]. Results of these four latter genotype profiles have been
previously reported [26].
4.3. Statistical Analyses
Associations between various phenotypic and genotypic metrics and the NaHCO3-
responsive vs. nonresponsive phenotypes were summarized in 2 × 2 cross-tabulation
tables, and analyzed by two-tailed Chi-square analytics and Fisher’s exact test where
appropriate. A Student’s t-test was used for comparisons of MRSA bioburdens within
the SEV model for each isolate. Determinations of sensitivity and specificity and their
statistical relevance, for a given set of criteria, were calculated by MedCalc statistical
software (https://www.medcalc.org/calc/diagnostic_test.php, accessed date: 13 January
2021). ROC analysis was performed using a web-based calculator (http://www.rad.jhmi.
edu/jeng/javarad/roc/JROCFITi.html, accessed date: 12 February 2021).
4.4. Pharmacodynamic Model with Ex Vivo Simulated Endocardial Vegetations (SEVs)
This ex vivo model was performed as described previously [27,52], to attempt to
recapitulate the in vitro designations of NaHCO3-responsive vs. nonresponsive phenotypes
(as predicted using the three-metric algorithm of AMC susceptibility, plus mecA and
spa genotyping). Three isolates fulfilling all three metrics were randomly selected and
compared ex vivo to three isolates not fulfilling these three metrics. SEVs consisted of
pooled human cryoprecipitate antihemophilic factor prepared from plasma (fibrinogen,
von Willebrand factor, factor VIII, factor XIII and fibronectin) and pooled platelets were
collected from human volunteer donors (UW Health Blood Bank, Madison, WI, USA).
Bovine thrombin (UW Health, Madison, WI, USA) and aprotinin (Sigma-Aldrich) were
commercially purchased. SEVs contain 3–3.5 g/dL of albumin and 6.8–7.4 g/dL of total
protein (equating to human physiologic levels) [53,54].
In the central fluid phase compartment, a 150 mL flask was prefilled with 100 mL
RPMI media, which contains 25 mM NaHCO3 and magnetic stir bar, and the SEVs were
added for 30 min prior to antibiotic dosing, to allow for climate acclimation. OXA (2 g) was
infused every 4 h (over 5 min) using a simulation derived from human PK/PD data (Cmin
2.3 µg/mL, half-life 1.0 h, ke 0.69/h) and standard dosing regimens for patients with severe
MRSA infections [55,56]. Samples of SEVs were taken at specified time points, weighed,
digested, and plated for MRSA quantification (CFU/g of SEV tissue).
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/antibiotics10091089/s1, Table S1: Phenotypic and genotypic characterization of NaHCO3-
responsive and nonresponsive MRSA strains, Table S2: Summary of statistical analyses of various
algorithms for identifying NaHCO3-responsive MRSA, Table S3: mecA sequencing primers.
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